Quantum Technology - The report highlights the clear positioning of the NISQ (Noisy Intermediate-Scale Quantum) era, indicating that current quantum devices are operational but limited in capability, lacking fault tolerance and scalability. Experts estimate that small-scale fault-tolerant quantum computers will take about ten years to develop [8][9] - The collaboration between Argonne National Laboratory and Intel has successfully deployed a 12-qubit silicon-based quantum processor, demonstrating the value of mature silicon technology in scaling quantum computing [10] - D-Wave has showcased a scalable on-chip low-temperature control gate model quantum bit, significantly reducing wiring costs and addressing a major bottleneck in the industry [12][14] Biomanufacturing - Micro Yuan Synthesis has secured nearly 300 million yuan in financing to accelerate the development of methanol biomanufacturing, which addresses the reliance on food-based raw materials in traditional biomanufacturing [15][16] - The first gene-consistent human "lung chip" has been developed, providing a new tool for personalized treatment of respiratory diseases and potentially revolutionizing drug development by reducing reliance on animal models [18] Hydrogen Energy and Nuclear Fusion - Policies in Shanghai and other regions are reducing the operational costs of hydrogen vehicles through subsidies and free highway access, which is expected to significantly boost the adoption of hydrogen fuel cell vehicles [19][20] - The report notes that hydrogen energy is transitioning from being a major electricity consumer to a "regulator" of the grid, enhancing the consumption of renewable energy and long-term storage capabilities [25][28] - The Energy Singularity's "Honghuang 70" nuclear fusion device has achieved a 120-second steady-state operation, marking a significant milestone in commercial nuclear fusion technology [31] - Dongsheng Fusion has completed a multi-hundred million yuan angel round of financing to develop a "deuterium-helium-3" fusion route, which is considered safer and more cost-effective than traditional methods [32][33] Brain-Computer Interface - Strong Brain Technology has raised 2 billion yuan to scale brain-computer interface technology, aiming to help one million disabled individuals regain social functionality within five to ten years [38][39] - Sichuan Province has set maximum prices for brain-computer interface medical services, which will take effect in April 2026, facilitating the clinical application of this technology [40][41] - The first brain-computer interface deep brain stimulator surgery in Southwest China has been successfully performed, providing new treatment options for Parkinson's disease [42][43] Embodied Intelligence - NVIDIA has released several physical AI models and frameworks that support robots in understanding physical laws, enhancing the industrialization of robots across various scenarios [5][13] - Chinese companies represent nearly 25% of robot exhibitors at CES 2026, with humanoid robots making up over 50% of the exhibition area, showcasing the competitive edge of Chinese firms in this sector [5][13] Sixth Generation Mobile Communication (6G) - Nanjing has launched a special plan to build a 6G industrial ecosystem, aiming for full coverage of 6G non-cellular networks by 2027 and the establishment of over 50 vertical industry scenarios [5][14]

Group 1: Market Observation - The three major indices experienced a strong upward trend, with the Shanghai Composite Index surpassing 4100 points and total trading volume exceeding 30 trillion, indicating a robust market structure [1] - The Vice Chairman of the China Securities Regulatory Commission, Chen Huaping, emphasized the need to improve the institutional environment for long-term investments and to enhance the effectiveness of regulatory enforcement [1] - As of the end of last year, various long-term funds held approximately 23 trillion yuan in A-share market value, a 36% increase from the beginning of the year, while equity fund sizes grew from 8.4 trillion yuan to around 11 trillion yuan [1] Group 2: SpaceX and Satellite Deployment - The FCC approved SpaceX's application to deploy an additional 7,500 second-generation Starlink satellites, increasing the total number of operational second-generation satellites to 15,000 [4] - SpaceX is required to launch at least 50% of the approved second-generation satellites by December 1, 2028, and complete the deployment of the remaining satellites by December 31, 2031 [4] Group 3: Chinese Satellite Industry - The Radio Innovation Institute was established in Xiong'an New Area, involving seven organizations, including China Electronics Technology Group and China Satellite Network Group, to support the development of China's satellite internet [5] - China Electronics Technology Group is deeply involved in the construction of low-orbit satellite internet constellations, covering the entire industry chain from satellite manufacturing to application services [6] - Key companies in the industry include GuoBo Electronics, which is a leading supplier of T/R components for phased array radars, and Chengchang Technology, which focuses on T/R chip design and production [11][8] Group 4: Neuralink and Market Impact - Neuralink announced plans to start large-scale production of brain-machine interface devices in 2026, which is expected to significantly reduce surgical risks and accelerate technology adoption [18] - Following this announcement, A-shares saw widespread price increases, with several stocks hitting their daily limit [18][19] Group 5: Competitive Market Dynamics - The market for brain-machine interface technology is characterized by strong news-driven volatility, with initial surges followed by differentiation among stocks [17][26] - Companies like Pulite and Sanbo Brain Science have seen significant stock performance due to their involvement in both brain-machine interface and commercial space sectors [21][28]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of January 11, 2026 [3] Core Insights - 2025 marked a significant year for Chinese innovative drugs going overseas, with total transaction amounts reaching $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs [4] - The innovative drug index saw a 35.31% increase in 2025, outperforming the CSI 300 index by 17.65% [4] - The trend of Chinese innovative drugs going global is expected to strengthen in 2026, with significant deals such as the one between Yilian Biotech and Roche for the YL201 project, which includes a $570 million upfront payment [4] - The small nucleic acid drug sector is experiencing breakthroughs, with GSK's Bepirovirsen showing positive results in Phase III trials for chronic hepatitis B, potentially becoming the first drug to achieve functional cure [5] - The report highlights the importance of oral autoimmune drugs, with Takeda's TYK2 inhibitor showing promising results in treating moderate to severe plaque psoriasis [6] - The brain-computer interface technology is entering a critical industrialization phase, with companies like Neuralink set to produce devices in 2026, supported by favorable policies and clinical trials in China [8] - The ZAP-X radiotherapy device is expected to capture a significant market opportunity in China, with the non-invasive tumor radiotherapy market projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024 [10] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 2.13% over the past week, ranking 25th among 31 industry indices [28] - Over the past month, the pharmaceutical industry index also lagged behind the CSI 300 by 5.42%, ranking 27th [29] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 36.95, above the five-year historical average of 31.12 [52] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral drugs, and the impact of policy support on the inhalation drug industry [55] 4. Important Industry Policies and News - Recent policies include the issuance of the fourth batch of encouraged generic drug directories by the National Medical Products Administration [57] - Significant news includes GSK's announcement of positive Phase III results for Bepirovirsen and Yilian Biotech's licensing agreement with Roche [58][59]

Industry Overview - Brain-Computer Interface (BCI) is a new cross-disciplinary technology that creates a communication channel between the brain and external devices, enabling direct information exchange [6] - BCIs can be classified into three types: invasive, semi-invasive, and non-invasive, with applications in medical rehabilitation, consumer interactions, and military fields [7] - The global BCI market is projected to reach $7.63 billion by 2029, growing from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% from 2019 to 2023 [13][14] - Over 1,500 financing events in the global BCI sector have raised nearly $10 billion, with significant investments in both the U.S. and China [16] Policy Guidance - Major countries have launched brain initiatives to support BCI development, with the U.S. investing approximately $4.5 billion in its BRAIN Initiative since 2013 [37][40] - China has initiated its "Brain Science and Brain-Like Intelligence Technology" project, with funding expected to reach hundreds of billions of yuan [39][42] Clinical Situation - The medical demand for BCIs is driven by the need for rehabilitation in stroke and disabled populations, with significant clinical research already underway for various diseases [3][33] - Clinical trials for BCIs are accelerating globally, with a rapid increase in the number of trials in China [3][11] Industry Progress - Notable advancements include Neuralink's implantation of over 10 devices and Synchron's achievement of brain-controlled iPad functionality [4][4] - Key overseas companies like Neuralink and Synchron are leading in the invasive BCI field, focusing on treatment and human-computer interaction [4][4] - Domestic companies are also making strides, with clinical trials accelerating and real-time Chinese language decoding being achieved [4][4] Industry Chain Analysis - The BCI industry chain consists of upstream hardware and software supply, midstream BCI product supply, and downstream applications in various fields [18] - Upstream technology innovation barriers are high, with breakthroughs in flexible electrodes and chips being critical [20][21] - Downstream applications are primarily in the medical field, which is the most mature area for commercialization [30]

Report Overview - The report is a weekly strategy report on overseas equity (Hong Kong and US stocks) by Guotai Junan Futures, dated January 11, 2026 [1][2] 1. Investment Ratings - No specific industry investment ratings are provided in the report 2. Core Views - For US stocks, maintain an optimistic outlook, continue with the technology + cyclical allocation strategy, and expect a more balanced market style in 2026 with a "shrinking circle" structure in the technology sector [3] - For Chinese stocks, in the short term, A-shares have better profit - making effects than Hong Kong stocks, and attention should be paid to the subsequent catch - up opportunities in Hong Kong stocks. In the medium term, Hong Kong stocks maintain a barbell strategy [4][7] 3. Summary by Sections US Stocks - **Market Performance and Outlook**: This week, cyclical sectors led the rise in US stocks, and the technology sector continued its "shrinking circle" structure. Next week, the US stock market will face earnings season and inflation data. The outlook remains optimistic, and the technology + cyclical allocation strategy continues [3] - **2026 Allocation Ideas**: The market style will be more balanced, and the K - shaped divergence between technology and non - technology, large - cap and small - cap stocks is expected to converge. Focus on AI technology, healthcare, utilities, finance, materials, and consumer sectors. Prioritize upstream infrastructure in AI technology over downstream software, and pay attention to theme investment opportunities in physical AI [3] - **Valuation**: US stock valuations are still relatively high overall [14] - **AI Bubble**: It is a local rather than a systematic bubble. The market is punishing individual companies with aggressive capital expenditures. Currently, it may be close to the 1997 position from the perspective of the technology industry's ROIC. Monitor the "ROIC - WACC" convergence trend and the divergence between "financing growth" and "profit growth" [20][22] Chinese Stocks - **Market Performance and Outlook**: This week, A - shares outperformed Hong Kong stocks. A - shares' performance was strong in some sectors with high performance certainty and theme - concept sectors. Southbound funds' entry momentum increased, and the pattern may be A - shares leading and Hong Kong stocks catching up. February is the month with the highest winning rate for A - shares historically [4][6][7] - **Short - term Allocation**: Defensively allocate sectors with high performance certainty (AI hardware, new energy leaders, and non - ferrous metals), and offensively allocate valuation - driven sectors (Hang Seng Technology, Hong Kong innovative drugs, commercial aerospace, and robotics) [7] - **Medium - term Allocation for Hong Kong Stocks**: Adopt a barbell strategy, focusing on technology assets with clear industrial trends supported by policies, some new energy sectors with supply - side clearance and demand - side improvement, and non - ferrous sectors benefiting from supply shortages, strong structural demand, and interest rate cuts [7] Odds Analysis - **Hong Kong Stocks**: The forward PE of the Hang Seng Index is 11.8 times, approaching the mean + 1STD since 2015. The forward PE of the Hang Seng Tech Index is 21.4 times, approaching the mean of the past 5 years. The Hang Seng Index ERP is 4.9%, and the Hang Seng Tech Index ERP is 1.1% [9][10]

Market Overview - The A-share market achieved a "good start" in 2026, with the Shanghai Composite Index recording 16 consecutive days of gains, setting a historical record for consecutive positive trading days. Major broad-based indices experienced widespread increases, indicating a recovery in market risk appetite, with growth and small-cap styles prevailing [1][21]. - Weekly trading volume in the A-share market surpassed 30 trillion yuan, with financing transactions becoming active and the financing balance exceeding 2.6 trillion yuan, marking a historical high. Key sectors such as commercial aerospace, satellite navigation, brain-computer interfaces, and nuclear fusion continued to attract attention, while related commodities also performed well [1][21]. Market Outlook - The current market conditions suggest a continuation of the bull market, with expectations for a spring trading window. Positive economic indicators, such as better-than-expected PMI and inflation data for December, provide fundamental support for the spring market. Additionally, there is a notable increase in the willingness of external funds to enter the market, with expectations for further inflows from insurance and resident funds [1][21][23]. Key Focus Areas - The increase in market volume has facilitated the index's breakthrough of previous highs. Since 2025, the A-share market has seen three instances of trading volume exceeding 30 trillion yuan, with the latest occurring on January 9, 2026. Following these volume spikes, the indices have consistently confirmed higher trading ranges, indicating a sustained upward trend [2][21]. - The influx of financing and foreign capital reflects a significant increase in market risk appetite. The financing balance reached a historical high of 2.6 trillion yuan, with financing transactions accounting for over 11.5% of total A-share trading volume, the highest level since November 2025. Notably, foreign capital transactions also surged, with northbound capital reaching 369.6 billion yuan, the highest since October 2025 [3][22]. Economic and Policy Environment - The economic fundamentals remain supportive, with both manufacturing and non-manufacturing PMIs returning to expansion territory in December. The CPI rose by 0.8% year-on-year, while the PPI decreased by 1.9%, both better than market expectations. The macroeconomic policy environment is favorable, with coordinated fiscal and monetary policies being implemented to support market liquidity [4][23]. - The industry configuration suggests a focus on technology themes such as AI applications, commercial aerospace, robotics, and domestic substitution, as well as sectors benefiting from price increases, such as chemicals and non-ferrous metals [4][23].

Group 1 - The core viewpoint emphasizes the need to actively seize the spring market, with AI applications expected to enter a main upward trend [1][2] - The spring market is showing continuous development, with rising risk appetite and significant potential in the computer sector due to low institutional holdings and substantial industry changes [1] - Recommendations include increasing positions in core leaders in AI applications and domestic computing power, as well as focusing on key targets in cutting-edge technology fields such as commercial aerospace, brain-computer interfaces, and digital currencies [1] Group 2 - AI applications are anticipated to experience a major upward trend, driven by positive industry developments and the entry of domestic large model manufacturers like Zhiyu and MiniMax into the Hong Kong stock market [2] - The market is closely watching the annual report expectations, with the potential for AI investments to shift from hardware to software, enhancing the upward potential of AI applications [2] - The outlook for the year suggests that AI applications will achieve more comprehensive and in-depth implementation, supported by continuous iterations in algorithms and computing power [2] Group 3 - The second chapter of the report focuses on the brain-computer interface industry, highlighting the imminent mass production of Neuralink and supportive domestic policies [3]

Group 1 - The A-share market experienced significant fluctuations this week, with the Shanghai Composite Index rising by 3.82%, the Shenzhen Component Index by 4.40%, and the ChiNext Index by 3.89%, indicating a notable increase in trading volume [1] - The medical services, military electronics, small metals, and semiconductor sectors saw the highest gains, with brain-computer interface and commercial aerospace concept stocks performing actively [1] - The brain-computer interface sector had substantial weekly gains, with Innovative Medical rising by 61.04%, Sanbo Brain Science by 56.15%, and Meihao Medical by 56.13% [1] Group 2 - Neuralink, owned by Elon Musk, announced plans to start mass production of brain-computer interface devices in 2026, aiming to reduce the implantation cost from $1 million to between $50,000 and $100,000 [1] - The National Medical Products Administration has initiated two industry standards for brain-computer interfaces, which will support future product registration and medical insurance pricing [1] - The National Healthcare Security Administration has established guidelines for the reimbursement of invasive brain-computer interface implantation and removal fees, with Hubei and Zhejiang provinces leading the implementation, potentially lowering the financial barrier for patients [1] Group 3 - The commercial aerospace sector remained active, with Shaoyang Hydraulic rising by 84.91% and Galaxy Electronics by 60.96% [2] - The "Three-Year Action Plan for Supporting Advanced Manufacturing Transformation and Upgrading (2026-2028)" issued on January 9 includes commercial aerospace as a key focus area, aiming to accelerate breakthroughs in commercial rockets and electric vertical takeoff and landing vehicles (eVTOL) [2] - Major funds saw net inflows exceeding 1 billion yuan in companies such as Huasheng Tiancheng, Dawi Technology, and Xian Dao Intelligent, while companies like Zhongji Xuchuang and New Yisheng experienced net outflows exceeding 4 billion yuan [2]

Market Performance - The North Exchange 50 Index increased by 5.82% compared to the previous week, while the Shanghai and Shenzhen 300 Index rose by 2.79% and the ChiNext Index by 3.89%[30] - The average market capitalization of North Exchange A-shares reached 3.197 billion yuan, with a daily average trading volume of approximately 26.13 billion yuan, up 34.57% from the previous week[5] Investment Recommendations - Focus on sectors with high industry prosperity and scarcity, particularly commercial aerospace, robotics, low-altitude economy, energy storage, solid-state batteries, and liquid cooling[40] - The PE ratios for North Exchange A-shares, ChiNext, Shanghai Main Board, Shenzhen Main Board, and Sci-Tech Innovation Board are 48.40, 45.54, 12.69, 24.07, and 78.26 respectively as of January 9, 2026[40] Economic Indicators - The Consumer Price Index (CPI) rose by 0.8% year-on-year in December 2025, marking the highest increase since March 2023[22] - The Producer Price Index (PPI) increased by 0.2% month-on-month in December 2025, but decreased by 1.9% year-on-year[22] Regulatory Developments - The People's Bank of China is expected to implement a prudent monetary policy, emphasizing the need for financial support for economic stability and growth in 2026[11] - The China Securities Regulatory Commission is intensifying efforts to combat financial fraud in the capital market, with 159 cases of financial fraud handled in 2024[18] Industry News - China applied for frequency resources for over 200,000 satellites in December 2025, indicating a significant expansion in the commercial aerospace sector[29] - The United Nations projects global economic growth at 2.7% for 2026, slightly lower than the 2.8% estimated for 2025, amid ongoing macroeconomic uncertainties[26]

Group 1: Institutional Research and Market Trends - A total of 116 listed companies conducted institutional research from January 5 to 9, with nearly 90% achieving positive returns as the market rose [1] - Notable stock performances included Pulit with a 42.59% increase, and Chengdu XianDao and BoRui ChuanBo both exceeding 30% [1] - Key areas of institutional interest included brain-computer interfaces, commercial aerospace, and AI applications, spurred by the recent central bank policy on digital currency [1] Group 2: Brain-Computer Interface Developments - The brain-computer interface (BCI) concept is currently a major market hotspot, with the Wind BCI index rising approximately 20% [4] - Elon Musk announced plans for large-scale production of BCI devices starting in 2026, indicating significant future market potential [4] - Companies like Dineike have made advancements in BCI technology, including prototypes for smart sleep devices and a low-frequency transcranial magnetic therapy device [4][6] Group 3: Commercial Aerospace Opportunities - The commercial aerospace sector is experiencing sustained interest, with the Wind commercial aerospace index also increasing by about 20% [7] - Chaojie Co. has engaged in multiple institutional research sessions, indicating a positive outlook for new client collaborations starting in Q1 [9] - The company focuses on manufacturing structural components for commercial rockets, which constitute over 25% of the total cost of a rocket [9] Group 4: Digital Currency Policy Changes - The central bank's new policy on digital currency, effective January 1, 2026, expands the role of digital RMB from cash-like to a broader monetary category [12] - This policy shift is expected to enhance banks' engagement and increase the application scenarios for digital RMB [12] - Tianyang Technology highlighted the need for banks to upgrade their IT systems to accommodate the new digital currency framework, particularly in payment systems [14]